Aquestive Therapeutics, Inc.

NasdaqGM:AQST 株式レポート

時価総額：US$415.8m

Aquestive Therapeutics マネジメント

マネジメント 基準チェック /24

Aquestive Therapeuticsの CEO はDan Barberで、 May2022年に任命され、 の在任期間は 2.5年です。 の年間総報酬は$ 2.50Mで、 24%給与と76%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の1.52%を直接所有しており、その価値は$ 6.31M 。経営陣と取締役会の平均在任期間はそれぞれ2.3年と2.2年です。

主要情報

Dan Barber

最高経営責任者

US$2.5m

報酬総額

CEO給与比率24.0%
CEO在任期間2.5yrs
CEOの所有権1.5%
経営陣の平均在職期間2.3yrs
取締役会の平均在任期間2.2yrs

経営陣の近況

Recent updates

Aquestive: Rare Opportunity With Dual Platform Strategy

Nov 05

Market Participants Recognise Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Revenues Pushing Shares 27% Higher

Sep 07
Market Participants Recognise Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Revenues Pushing Shares 27% Higher

Aquestive Therapeutics: Robust Development Of Oral Emergency Therapies Will Likely Pay Off Into 2025

Aug 20

Rainbows and Unicorns: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Analysts Just Became A Lot More Optimistic

Aug 11
Rainbows and Unicorns: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Analysts Just Became A Lot More Optimistic

What Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) 30% Share Price Gain Is Not Telling You

Jul 24
What Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) 30% Share Price Gain Is Not Telling You

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless

May 22
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless

Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024

Apr 09

Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Shares Climb 30% But Its Business Is Yet to Catch Up

Feb 28
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Shares Climb 30% But Its Business Is Yet to Catch Up

Aquestive Therapeutics: Anaphylm's Top-Line Data Could Reveal A Game-Changer In Q1

Jan 19

Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Popularity With Investors Is Under Threat From Overpricing

Jan 05
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Popularity With Investors Is Under Threat From Overpricing

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Surges 63% Yet Its Low P/S Is No Reason For Excitement

Apr 17
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Surges 63% Yet Its Low P/S Is No Reason For Excitement

Aquestive Therapeutics receives positive FDA response for AQST-109 epinephrine for severe allergic reaction

Oct 11

Aquestive Therapeutics, Pharmanovia ink licensing & supply pact for Libervant buccal film

Sep 28

Aquestive Therapeutics: FDA Stymies Libervant Launch

Sep 05

Aquestive Therapeutics: A First Take

Aug 29

CEO報酬分析

Aquestive Therapeutics の収益と比較して、Dan Barber の報酬はどのように変化したか？
日付総報酬給与会社業績
Sep 30 2024n/an/a

-US$35m

Jun 30 2024n/an/a

-US$26m

Mar 31 2024n/an/a

-US$29m

Dec 31 2023US$2mUS$600k

-US$8m

Sep 30 2023n/an/a

-US$12m

Jun 30 2023n/an/a

-US$23m

Mar 31 2023n/an/a

-US$33m

Dec 31 2022US$1mUS$542k

-US$54m

Sep 30 2022n/an/a

-US$71m

Jun 30 2022n/an/a

-US$73m

Mar 31 2022n/an/a

-US$69m

Dec 31 2021US$1mUS$424k

-US$71m

Sep 30 2021n/an/a

-US$62m

Jun 30 2021n/an/a

-US$64m

Mar 31 2021n/an/a

-US$54m

Dec 31 2020US$840kUS$410k

-US$56m

Sep 30 2020n/an/a

-US$48m

Jun 30 2020n/an/a

-US$50m

Mar 31 2020n/an/a

-US$68m

Dec 31 2019US$1mUS$389k

-US$66m

Sep 30 2019n/an/a

-US$68m

Jun 30 2019n/an/a

-US$64m

Mar 31 2019n/an/a

-US$80m

Dec 31 2018US$2mUS$319k

-US$61m

Sep 30 2018n/an/a

-US$61m

Jun 30 2018n/an/a

-US$38m

Mar 31 2018n/an/a

-US$8m

Dec 31 2017US$899kUS$300k

-US$14m

報酬と市場: Danの 総報酬 ($USD 2.50M ) は、 US市場 ($USD 2.16M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Danの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Dan Barber (48 yo)

2.5yrs

在職期間

US$2,496,141

報酬

Mr. Daniel Barber, also known as Dan, is the Chief Executive Officer, President and Director at Aquestive Therapeutics, Inc. since May 17, 2022 and served as its Senior Vice President since April 2014 unti...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Daniel Barber
CEO, President & Director2.5yrsUS$2.50m1.52%
$ 6.3m
A. Toth
Chief Financial Officer3.9yrsUS$1.12m0.43%
$ 1.8m
Lori Braender
General Counsel6.2yrsUS$1.19m0.52%
$ 2.2m
Cassie Jung
Chief Operating Officer2yrsデータなし0.25%
$ 1.0m
Alexander Schobel
Chief Innovation & Technology Officer9.9yrsUS$810.02k1.08%
$ 4.5m
Stephen Wargacki
Chief Science Officerno dataデータなし0.28%
$ 1.2m
Sherry Korczynski
Senior Vice President of Sales & Marketingless than a yearデータなし0.027%
$ 114.0k
Peter Boyd
Senior Vice President of Information Technology & Human Resources1.7yrsデータなし0.26%
$ 1.1m
Gary Slatko
Chief Medical Officerno dataデータなしデータなし
Carl Kraus
Chief Medical Officer1.4yrsデータなし0.28%
$ 1.1m
Robert Arnold
VP of Financeno dataデータなしデータなし

2.3yrs

平均在職期間

58yo

平均年齢

経験豊富な経営陣: AQSTの経営陣は 経験豊富 であると考えられます ( 2.3年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Daniel Barber
CEO, President & Director2.5yrsUS$2.50m1.52%
$ 6.3m
Timothy Morris
Independent Director2.3yrsUS$145.23k0%
$ 0
Gregory Brown
Independent Chairman of the Board17.7yrsUS$150.77k0.082%
$ 342.4k
Julie Krop
Independent Director3.8yrsUS$137.69k0%
$ 0
John Cochran
Independent Vice Chairman of the Board20.8yrsUS$137.23k0.11%
$ 453.6k
Marco Taglietti
Independent Director3.8yrsUS$121.78k0%
$ 0
Carlos Camargo
Member of Scientific Advisory Board2.2yrsデータなしデータなし
Ruchi Gupta
Member of Scientific Advisory Board2.2yrsデータなしデータなし
David Bernstein
Member of Scientific Advisory Board2.2yrsデータなしデータなし
David Fleischer
Member of Scientific Advisory Board2.2yrsデータなしデータなし
Matthew Greenhawt
Member of Scientific Advisory Board2.2yrsデータなしデータなし
Jay Lieberman
Member of Scientific Advisory Board2.2yrsデータなしデータなし

2.2yrs

平均在職期間

61yo

平均年齢

経験豊富なボード: AQSTの 取締役会 は 経験豊富 ではない ( 2.2年の平均在任期間) ため、新しい取締役会が必要であると考えられます。